new drug application - Robuta Search

https://www.prnewswire.com/news-releases/acepodia-announces-fda-clearance-of-investigational-new-drug-application-for-ace2016-a-first-in-class-allogeneic-anti-egfr-cell-therapy-302052466.html Acepodia Announces FDA Clearance of Investigational New Drug Application for ACE2016, a... Feb 4, 2024 - /PRNewswire/ -- Acepodia (6976:TT), a clinical stage biotechnology company developing first-in-class cell therapies with its unique Antibody-Cell Conjugation... new drug application fda clearance https://www.prnewswire.com/news-releases/acepodia-announces-fda-clearance-of-investigational-new-drug-application-for-ace1831-in-igg4-related-disease-302306506.html Acepodia Announces FDA Clearance of Investigational New Drug Application for ACE1831 in... Nov 15, 2024 - /PRNewswire/ -- Acepodia (6976:TT), a clinical-stage biotechnology company developing first-in-class cell therapies with its unique Antibody-Cell Conjugation... new drug application fda clearance https://www.drugpatentwatch.com/p/NDA/213953 Kyzatrex / testosterone undecanoate FDA New drug application 213953 global drug patent coverage,... Get details on NDA 213953 international drug patents, generic equivalents and API sources new drug application testosterone undecanoate global patent fda https://acnnewswire.com/press-release/english/88761/eisai-submits-new-drug-application-for-mecobalamin-ultrahigh-dose-formulation-in-japan-for-the-indication-of-amyotrophic-lateral-sclerosis Eisai Submits New Drug Application for Mecobalamin Ultrahigh-Dose Formulation in Japan for the... Eisai Co., Ltd. announced today that it has submitted a New Drug Application (NDA) for ultrahigh-dose mecobalamin (development code: E0302) for the indication... new drug application https://www.prnewswire.com/news-releases/tr1x-announces-fda-clearance-of-first-investigational-new-drug-application-for-trx103-an-allogeneic-regulatory-t-cell-therapy-to-treat-autoimmune-diseases-302112587.html Tr1X Announces FDA Clearance of First Investigational New Drug Application for TRX103, an... Apr 10, 2024 - /PRNewswire/ -- Tr1X, Inc., an autoimmune and inflammatory disease cell therapy company focused on the development of novel allogeneic regulatory T cell... new drug application https://www.financialstrend.com/spectrum-pharmaceuticals-inc-nasdaqsppi-resubmits-new-drug-application-for-evomela-23736.html Spectrum Pharmaceuticals, Inc (NASDAQ:SPPI) Resubmits New Drug Application For EVOMELA | Financial... new drug application https://mrr.dawnbreaker.com/portals/medical/drugs/investigational-new-drug-ind-application/ Investigational New Drug Application | Dawnbreaker MRR new drug application dawnbreaker mrr https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-submits-new-drug-application-to-the-fda-for-fostemsavir-an-investigational-first-in-class-attachment-inhibitor-for-the-treatment-of-hiv-in-adults/ ViiV Healthcare submits New Drug Application to the FDA for fostemsavir, an investigational,... ViiV Healthcare completed submission of a New Drug Application (NDA) to the US Food and Drug Administration (FDA). new drug application https://www.artixio.com/post/new-drug-application-nda-meaning-approval-process New Drug Application (NDA): Meaning, Types & FDA Approval Apr 22, 2026 - Learn about New Drug Application (NDA), its types, FDA approval process, timeline, components, and submission requirements in this complete guide. new drug application nda meaning types fda https://www.ddregpharma.com/what-is-supplemental-new-drug-application What is Supplemental New Drug Application (sNDA)? Supplemental New Drug Application (sNDA) is a request to the FDA to change an already approved drug in the market. new drug application what is supplemental snda https://www.novumpr.nl/2026/01/05/takeda-and-protagonist-announce-submission-of-new-drug-application-nda-for-rusfertide-for-treatment-of-polycythemia-vera-pv/ Takeda and Protagonist Announce Submission of New Drug Application (NDA) for Rusfertide for... new drug application https://www.salamancapress.com/2025/03/06/genassist-ltd-announces-fda-clearance-of-investigational-new-drug-application-for-gen6050x-a-globally-first-in-class-base-editing-drug-for-duchenne-muscular-dystrophy/ GenAssist Ltd Announces FDA Clearance of Investigational New Drug Application for GEN6050X, a... Mar 7, 2025 - SUZHOU, China, March 6, 2025 /PRNewswire/ -- On March 06, 2025, GenAssist Ltd (GenAssist), a pioneering gene-editing biotechnology company specializing in... new drug application https://www.novumpr.nl/2024/07/02/vertex-announces-fda-acceptance-of-new-drug-application-for-vanzacaftor-tezacaftor-deutivacaftor-a-next-in-class-triple-combination-treatment-for-cystic-fibrosis/ Vertex Announces FDA Acceptance of New Drug Application for Vanzacaftor/Tezacaftor/Deutivacaftor, a... new drug application https://www.drugdiscoveryonline.com/doc/brc-therapeutics-announces-investigational-new-drug-application-brc-cleared-by-fda-0001 BRC Therapeutics Announces Investigational New Drug Application For BRC-002 Cleared By FDA BRC Therapeutics (BRC), a pharmaceutical company developing therapeutics for neurological and inflammatory diseases, announced today that the company can... new drug application